Immunotherapy Scientist, Peter MacCallum Cancer Centre
| Role | Organisation | Sources |
|---|---|---|
| BEAT Inventor (former) | Currus Biologics | Brandon BioCatalyst, Main Sequence |
| Immunotherapy Scientist (former) | Peter MacCallum Cancer Centre | Brandon BioCatalyst, Main Sequence, Brandon Capital portfolio (Mon 28 Jun 2021), Brandon BioCatalyst portfolio (Mon 28 Jun 2021), Brandon BioCatalyst portfolio (Mon 28 Jun 2021), Brandon Capital portfolio (Mon 28 Jun 2021) |
Stories naming Dr Clare Slaney. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Profile of a Peter Mac spinout advancing solid-tumour cell therapies; recounts its Series A backers, later investment, grant support, and chief executive Sam Cobb's earlier career building and listing AdAlta.
Main Sequence explains why it backed Currus Biologics, whose BEAT platform aims to make CAR-T cell therapies effective against solid tumours, starting with mesothelin-positive cancers, as the team prepares for a clinical trial.
Melbourne cancer immunotherapy startup Currus Biologics, spun out of Peter MacCallum, raised $10 million led by the Brandon Capital-managed Medical Research Commercialisation Fund with Uniseed, to advance its BEAT technology toward human trials.
Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·SmartCompany·Startup Daily·SmartCompany·Startup Daily